Home > Oncology > ASCO 2020 > Lung Cancer > Tiragolumab and atezolizumab: ORR in NSCLC

Tiragolumab and atezolizumab: ORR in NSCLC

Tiragolumab and atezolizumab showed improved objective response rate over placebo and atezolizumab in chemotherapy-naïve locally advanced or metastatic non-small cell lung cancer (NSCLC).

Dr Delvys Rodriguez-Abreu (NYU Perlmutter Cancer Center, USA) presented the phase 2 CITYSCAPE trial, which tested chemotherapy-naïve patients with PD-L1-positive, locally advanced or metastatic NSCLC [1]. Participants were randomised to the combination of tiragolumab and atezolizumab (n=67) or placebo plus atezolizumab (n=68). Co-primary endpoints were investigator-assessed objective response rate (ORR) and progression-free survival (PFS).

The primary analysis indicated that tiragolumab/atezolizumab improved ORR and median PFS compared with placebo/atezolizumab. The ORR was 31.3% in the tiragolumab arm versus 16.2% in the placebo arm. The median PFS was 5.4 months and 3.6 months in the tiragolumab and pl...



please login to read the entire article:


You need to register to read the entire article, please do so now.





Posted on